France· FR:67507605
ERIVEDGE 150 mg, gélule
A medicinal product containing vismodégib, registered in France by ROCHE REGISTRATION (ALLEMAGNE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- VISMODÉGIB
- Manufacturer
- ROCHE REGISTRATION (ALLEMAGNE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009274767781 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 28 gélule(s)EUR 3.84
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vismodégib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayErivedgeRoche Registration GmbH
- FinlandErivedgeParanova Oy
- SwitzerlandErivedge
- CzechiaERIVEDGERoche Registration GmbH, Grenzach-Wyhlen
- SpainERIVEDGE 150 MG CAPSULAS DURASRoche Registration Gmbh
- United KingdomErivedge 150mg capsulesRoche Products Ltd
- IrelandErivedge 150 mg hard capsulesRoche Registration GmbH
- IcelandErivedgeRoche Registration GmbH*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Erivedge
- Liechtenstein · Erivedge
- Norway · Erivedge
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/47942749-ff0a-4ebd-91ca-fb921fdc5347 GET /v1/drugs/47942749-ff0a-4ebd-91ca-fb921fdc5347?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67507605",
"date_amm": "2013-07-12",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/13/848",
"substance": "VISMODÉGIB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about vismodégib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.